The Hatch-Waxman Playbook: How Generic Drugmakers Use Patent Litigation to Get to Market Early
Introduction: The Law That Reshaped American Medicine In 1984, a California congressman named Henry Waxman and a Utah senator named […]
How to Offer Abuse-Deterrent Reformulation Packages Before Drug Patent Loss of Exclusivity — and Win the Contract
The Problem With Waiting Most formulation vendors approach business development reactively. They wait for a drug to lose exclusivity, watch
Old Drugs, New Signals: What the Side-Effect Conversation is Really Saying
There’s a quiet shift happening in pharmacology that doesn’t show up neatly in prescribing guidelines or FDA labels. It shows
Old Drugs, New Signals: What the Side-Effect Conversation is Really Saying Read Post »
What a Drug Patent Is Really Worth: How Litigation Costs Reshape Acquisition Value
The Number Nobody Puts in the Model Every pharma M&A deal starts with a revenue forecast. Bankers build complex discounted
What a Drug Patent Is Really Worth: How Litigation Costs Reshape Acquisition Value Read Post »
Two Clocks, One Drug: How Patents and FDA Exclusivity Actually Determine When Your Drug Faces Competition
Every pharmaceutical executive knows the word “patent cliff.” Fewer can accurately define the legal machinery underneath it. Fewer still understand
Small Molecule vs. Biologic: Tailoring Your Drug Patent LOE Strategy for Generics vs. Biosimilars
Why Your LOE Strategy Depends on Molecule Type A brand-name drug losing its final patent is not one event. It
Win the Tender: A Business Development Guide for Biopharma Commercial Vendors Selling Tender Strategy Consulting in EU Markets Timed Around Drug Patent Loss of Exclusivity Dates
Every year, billions of euros in pharmaceutical procurement value shifts from branded drug budgets to competitive tender processes across the
New Drug, Old Molecule: How Pharma Extracts Billions from Mature Drugs Through New Indications
Methods-of-use patents have quietly become the pharmaceutical industry’s most underappreciated exclusivity tool. Here’s how they work, who’s using them, and
Sell to the Drug Patent Cliff: How Biopharma Packaging Companies Win Deals by Tying Serialization and Anti-Counterfeit Solutions to Drug Patent Loss of Exclusivity
The Window You Cannot Miss Every drug patent that expires is a commercial event for at least a dozen industries.
